Clinical Trial Ahead for TB Antibiotic
A promising new tuberculosis antibiotic, PA-824, is set to enter a clinical trial.
Akinso: A promising new tuberculosis antibiotic — "PA-824" — is set to enter a clinical trial. The National Institute of Allergy and Infectious Diseases — and the non-profit, New York-based Global Alliance for TB Drug Development — contributed to the antibiotic's pre-clinical testing in animals. Now, "PA-824" will be tested at a medical clinic in Lincoln, Nebraska — according Doctor Barbara Laughon [like "lawn"], Chief of the Complications and Co-infections Research Branch in the Division of AIDS at the NIAID.
Laughon: What the scientific community is hoping this drug will do is — after the trials are done to establish its safety and its effectiveness — that it may indeed make the treatment of tuberculosis shorter and more efficient — thereby saving a large number of lives in places around the world affected by both tuberculosis and HIV/AIDS.
Akinso: For more information, visit http://www.tballiance.org/. This is Wally Akinso, at the National Institutes of Health, Bethesda, Maryland.
About This Audio Report
Reporter: Wally Akinso
Sound Bite: Dr. Barbara Laughon
Topic: TB, tuberculosis